Thanks for the information!
So, conceivably, we might not see a PR from the FDA or KERX until next Tuesday morning, according to this information?
Yep, but that's only part of the story.
INO's pipeline DWARFS the pipeline of ONCS. So, longer term, expect INO to outperform ONCS.
Thus, I'm heavily invested in ONCS and not as much with INO. Both will ultimately do well.
I don't believe this is of much significance either way.
As mentioned before, most CEOs sit on boards of non-competing companies.
The PPS should not be affected by this unless it causes current shareholders (who follow the news) to sell. Any new money coming into the company based on Acorn pumping will not even be aware of this event. And this news will have no affect on any existing ONCS catalysts on the horizon.
A complete non-starter for substantive news, which is being blown out of proportion, IMHO.
What's best for marketing is probably also best for the PPS.
They should not be mutually exclusive around FDA approval.
And especially since their pipeline is MUCH larger than ours.
But we will make it to market sooner.
Those are the dynamics.
He's not only wrong, he's showing off his age, immaturity, intelligence, and potential agenda.
Moral of the story?
No balls and a small dick don't make 3 widgets of sense.
The market cap remains the same, reverse split or not.
The company needs solid catalysts to move ahead of INO and a product on the market.
Their market cap is currently 6X what ours is: $649M to $108M. That's a lot of ground to make up.
My guess is 15-20%. Much of the approval is already baked in, or we would see a much larger pop, IMHO.
The wild card is the short interest, and how that plays out.
It's impossible to predict the exact price action, but my guess is that we will see $20-25 very soon.
Yep, this is an off-topic post.
I suppose you're equating a long position as a single call option. I can see the analogy. But a long position is not a call option. Two different things. No worries. We can agree to disagree.
OK, back to our regularly scheduled program.
ONCS, up, up and away!
What, a phone call? ;)
Seriously, what equity has call options priced that high to allow such a high profit on a SINGLE call? I know of none. Would love to be educated on this one...
It depends. I bought and sold 25 calls. The total commission was $76.55.
Including commissions, my basis was $913.25 and the payout including commissions was $1,836.70, for a two-day return of just over 100% (101.1%).
I call that a "short-term double." :)
KERX at leas temporarily crushed it today.
I bought Sept $20 calls for 0.35 on Friday and sold them for 0.75 today.
I personally believe a fair amount is baked in, but I still think we might see a $20+ pop on FDA approval, followed by a "sell on the news." They are a prime buyout candidate too; hence, the pop today. A buyout would be in the mid-to-high 20s, IMHO.